Plain-English translation of NCT07570719 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing whether two blood biomarkers—phosphorylated tau 217 to amyloid beta 42 ratio (pTau217/Aβ42) and glial fibrillary acidic protein (GFAP)—can reliably detect Alzheimer's disease and mild cognitive impairment in older adults in a real-world setting. If your blood test shows abnormal results, you will complete additional memory and thinking assessments to see if cognitive changes are present.
Currently, diagnosing Alzheimer's disease often requires expensive brain imaging or spinal fluid tests. This trial aims to discover whether simple blood tests could become a practical, affordable way to screen for early Alzheimer's disease in community settings, especially in Chinese older populations where baseline levels for these markers are not yet well established.
You likely qualify if…
You likely don't qualify if…
You will have a blood sample taken to measure the two biomarkers. If your blood test results are abnormal, you will be asked to complete cognitive assessments including memory tests and questionnaires about mood and daily activities. A random 15% of participants with normal blood test results will also complete these same assessments. The study follows a real-world screening approach, so visits and timing will be integrated with your routine healthcare.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China